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SUMMARY  
Setting and objective: To describe trends in drug-resistant tuberculosis in two gold mining 
workforces, South Africa, 2002-8. 
Design: Tuberculosis programme data analysis. 
Results: Tuberculosis case notification rates decreased between 2002-8, from 4006 to 
3018/100000 and 3192 to 2468/100000 for companies A and B respectively. HIV prevalence 
exceeded 80% in tuberculosis episodes with known status. The proportion of tuberculosis 
episodes with multi-drug resistance (MDRTB) increased: among previously treated cases, 
from 6/129 (4.7%) to 17/85 (20.0%) and from 4/38 (10.4%) to 7/28 (25.0%) in companies A 
and B respectively (tests for trend, p<0.001 company A; p=0.304 company B). Case 
notifications of MDRTB increased during 2002-8, from 39.8 to 122.9/100000/year in 
company A and 57.8 to 96.8/100000/year in company B. Coverage of second-line drug 
susceptibility testing among MDRTB episodes was low. Previous treatment exposure was a 
strong risk factor for MDRTB (prevalence ratio 8.78 [95% confidence interval 5.94 – 12.97] in 
previously treated versus untreated).  
Conclusion: Despite decreasing tuberculosis notifications overall, notifications of MDRTB 
and proportions of episodes with MDR increased in the larger company. Cure must be 
ensured in first episodes to prevent acquired resistance. Improved coverage of culture, drug 
susceptibility testing and HIV testing is required to allow treatment to be optimised. 
 
Keywords: Multi-drug resistance, HIV, drug susceptibility testing, isoniazid, rifampicin 
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INTRODUCTION 
Tuberculosis case notification rates (CNR) among gold miners in South Africa are very high, 
exceeding 4000/100000 in 1999 [1], compared with 960/100000 nationally in South Africa in 
2008 [2], attributable to high prevalence of HIV (29% in 2001) and silicosis [3, 4]. In the 
1990s, the proportion of tuberculosis episodes with multi-drug resistance was stable and 
relatively low in miners [5, 6], estimated at 1.0% and 2.8% among previously untreated and 
previously treated episodes respectively [5]. More recently in South Africa, transmission of 
drug-resistant tuberculosis and resistance to second line antituberculous agents has been 
reported in association with HIV treatment facilities [7] and gold miners [8].  
The aims of this study were: 1) to describe trends in CNR and prevalence of drug resistance 
among tuberculosis episodes from 2002-8; 2) to analyse the effect of previous tuberculosis 
treatment and HIV infection on drug resistance in a gold mining workforce, in a period 
preceding a large-scale tuberculosis prevention intervention. 
 
STUDY POPULATION AND METHODS 
We analysed routine data from 2002-8 in two mining companies in Gauteng province, South 
Africa (companies A and B). From 2006, companies participated in "Thibela TB", a cluster-
randomised trial of community-wide isoniazid preventive therapy (IPT) [9]. Of seven mine 
shafts contributing data for this analysis, two were intervention (starting June and July 2007) 
and five control clusters.  
Tuberculosis episodes were included in this study if treatment started between 1st January 
2002 and 31st December 2008. Episodes were then included in analysis of drug resistance if 
they were culture positive for Mycobacterium tuberculosis (without concurrent non-
tuberculous mycobacteria (NTM)), with drug susceptibility testing (DST) results available for 
at least isoniazid and rifampicin.  
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Policy in both companies from 2002-8 was to perform culture and DST for rifampicin and 
isoniazid routinely for retreatment cases and cases responding poorly to treatment. 
Company A also routinely tested previously untreated cases. Second-line DST was only 
performed among multi-drug resistant tuberculosis (MDRTB) episodes after 2006. Medical 
records (electronic where available, supplemented by paper records), laboratory records and 
tuberculosis registers were reviewed retrospectively.  For paper-based source data, for 
logistic reasons, complete data were only extracted for episodes with DST results.  
Definitions  
The CNR was defined as the number of tuberculosis treatment episodes recorded in the 
tuberculosis register during a given period of time, per 100000 population, with denominators 
calculated as below (see "data analysis"). 
HIV status was defined as positive if a positive rapid test or ELISA result was recorded 
before tuberculosis treatment was started or up to six months afterwards, and negative if a 
negative result was recorded after the start of tuberculosis treatment or up to six months 
before.  
Drug resistance in previously untreated versus previously treated cases was defined as 
drug-resistant tuberculosis occurring in an individual with fewer than 30 versus 30 or more 
days previous tuberculosis treatment exposure. Changes in drug susceptibility during 
treatment were also counted as episodes of drug resistance in previously treated cases and 
included in calculating CNR for drug-resistant tuberculosis and prevalence ratios for drug 
resistance by treatment history and HIV status. 
MDRTB was defined as M. tuberculosis resistant to at least rifampicin and isoniazid. 
Rifampicin and isoniazid monoresistance were defined as M. tuberculosis resistant to 
rifampicin but not isoniazid and isoniazid but not rifampicin, respectively. 
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Data analysis  
In order to avoid counting re-registrations of the same tuberculosis disease episode, which 
can occur when treatment is interrupted and then restarted, we excluded re-registrations for 
the same individual within six months after the planned end of treatment, unless there was a 
change in drug susceptibility between registrations, for calculations of CNR for and 
proportions with resistance. In calculating DST coverage (company A), episodes with mixed 
M. tuberculosis and NTM isolated were excluded from numerator and denominator to allow 
for difficulties in interpreting DST. Episodes included in the calculation of CNR, but excluded 
from estimates of episodes with DST, comprised those excluded for re-registrations; cultures 
not done; culture negative; no DST; cultures positive for NTM only or mixed M. tuberculosis/ 
NTM. Prevalence ratios were analysed using combined data from both companies. For 
calculating proportions with drug resistance, denominators comprised episodes with DST 
available. Based on existing literature [10] we anticipated that previous treatment would be 
the main risk factor for drug resistance. We also investigated the role of HIV infection. Chi-
squared tests were used to compare proportions and the score test for trend to assess for 
linear trend. The Poisson model was used to assess for linear trend and departures from 
linear trend in CNR by year. Where there was evidence for departure from linear trend the p-
value for the overall test is quoted. 
Company workforce data (mean workforce size each calendar year) were used to estimate 
denominators for CNR. Company A provided monthly figures from September 2003; 
company B provided 1-8 figures annually from September 2003. September 2003 
denominators were used for earlier estimates. Permanent employees and short term 
contractors were included in denominators, since both contributed to numerators.  
Data were entered using EpiData (www.epidata.dk) and analysed using STATA v10 (STATA 
Corporation, Texas).  
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Laboratory methods  
From 2002 laboratories serving mine health services performed culture and DST using 
BACTECTM Mycobacterial Growth Indicator Tube 960 system [BD Diagnostics System, 
Sparks MD]. 
Ethical approval 
Research Ethics Committees of the London School of Hygiene and Tropical Medicine and 
the University of KwaZulu Natal approved the study.  
 
RESULTS  
Study population 
Workforce size, 2002-8, ranged from 15239 to 19476 (company A) and from 6671 to 8414 
(company B). Median age was 42 years (interquartile range [IQR] 37, 47 years) for company 
A and 44 years (IQR 40, 48) for company B.  
Numbers included in analysis and case notification rates (CNR) 
In company A, with 4268 tuberculosis episodes registered from 2002-8, CNR decreased 
from 4006/100000 in 2002 to 3018/100000 in 2008 (overall p<0.001). Of 4268 episodes 
registered, exclusions from the analyses for this study were: 1807 not culture positive; 78 re-
registrations; 133 mixed M. tuberculosis/NTM; 243 lacked DST for isoniazid and/or 
rifampicin. Therefore 2007/4268 (47.0%) registered, culture positive M. tuberculosis 
episodes with DST for rifampicin and isoniazid were included in analyses for company A 
(figure 1). Of these, 617/2007 (30.7%) were retreatment episodes. Five episodes with 
change in drug susceptibility during treatment were also included. 
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For company B, 1472 episodes were registered from 2002-8 and CNR decreased from 
3192/100000 in 2002 to 2468/100000 in 2008 (test for trend, p<0.001). Of 1472 episodes 
registered, exclusions from the analyses for this study were: 1014 not culture positive or 
culture positive with DST not available for rifampicin and/or isoniazid; 43 re-registrations. 
Therefore 415/1472 (28.2%) registered, culture positive M. tuberculosis episodes with DST 
for rifampicin and isoniazid were included in the below analyses for company B (figure 1). Of 
these, 200/415 (48.2%) were retreatment episodes. Four episodes with change in drug 
susceptibility during treatment were also included. 
CNR and numbers of culture-positive M. tuberculosis episodes with DST for rifampicin and 
isoniazid after all exclusions are shown in figure 2. 
Coverage of drug susceptibility testing  
For company A, first-line DST (at least rifampicin and isoniazid) was done in 2007/2250 
(89.2%) of M. tuberculosis culture-positive episodes. For episodes registered as retreatment 
episodes, DST coverage was 617/691 (89.3%) in total and 82/82 (100%) in 2008. Coverage 
was not calculable for company B as complete data were only collected on episodes with 
DST available. 
HIV prevalence 
In company A, from 2002-8, HIV status was documented for 1329/2012 (66.1%) episodes 
with DST available. Of these, 1160 (87.3%) were HIV-infected. The prevalence of HIV 
infection increased from 149/173 (86.1%) in 2002 to 153/167 (91.6%) in 2008 (test for trend 
p=0.086). 
In company B, from 2002-8, HIV status was documented for 157/419 (37.5%) episodes with 
DST available. Of these, 135 (86.0%) were HIV-infected.  
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Trends in drug-resistant tuberculosis: case notification rates (previously treated and 
untreated cases combined) 
In company A, MDRTB CNR increased from 39.8/100000/year in 2002 to 122.9/100000/year 
in 2008 (test for trend p=0.004) and CNR for isoniazid monoresistant episodes changed by 
year (overall p<0.001) without linear trend. CNR for rifampicin monoresistant episodes was 
17.1/100000 in 2002 and 55.3/100000 in 2008. In company B, MDRTB CNR increased from 
57.8/100000/year in 2002 to 96.8/100000/year in 2008 and CNR for isoniazid monoresistant 
episodes was 72.2/100000 in 2002 and 72.6/100000 in 2008, neither showing evidence of 
linear increase (tests for trend, p=0.65 and p=0.73 respectively) (figure 3). 
 
Trends in drug resistance among previously untreated cases  
In company A, the proportion of previously untreated cases with MDRTB rose from 2/245 
(0.8%) in 2002 to 3/125 (2.4%) in 2008 (test for trend, p=0.005). In company B, few MDRTB 
episodes were registered among previously untreated cases (figure 4). 
 
Trends in drug resistance among previously treated cases 
In company A, MDRTB occurred in 6/129 (4.7%) of episodes with previous treatment 
exposure in 2002 and 17/85 (20.0%) in 2008 (test for trend p<0.001). Rifampicin 
monoresistance occurred in 2/129 (1.6%) in 2002 and 7/85 (8.2%) in 2008 (figure 5). 
In company B only two episodes were rifampicin monoresistant. MDRTB occurred in 4/38 
episodes (10.4%) in 2002 and 7/28 (25.0%) in 2008 (test for trend, p=0.304) (figure 5). 
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Second-line DST 
From 2002-8, in company A, 88/124 (71.0%) of MDRTB cases were tested for ethambutol 
and streptomycin susceptibility and 48/88 (54.5%) were resistant to both drugs. In company 
B, 11/44 (25.0%) of MDRTB cases were tested:  8/11 were streptomycin resistant, with 3/8 
also ethambutol resistant. 
For company A, 7/69 MDRTB episodes in 2006-8 had second line DST results available. In 
company B, second line DST was documented in 1/20 MDRTB episodes in 2006-8. 
 
Drug resistance by previous treatment exposure and HIV status 
Table 1 shows the proportions with drug resistance among previously treated versus 
untreated episodes. Previous treatment was a strong risk factor for drug resistance, with 
prevalence ratio for MDRTB of 8.78 (95% confidence interval [CI] 5.94 – 12.97) and for 
rifampicin monoresistance of 6.11 (95% CI 2.60 – 14.37) in previously treated versus 
untreated cases. Previous treatment exposure was less strongly associated with isoniazid 
monoresistance (prevalence ratio 1.45 [95% CI 1.15 – 1.83]). Results were very similar 
when stratified by company (data not shown). 
Among previously untreated episodes, there was no evidence of association between HIV 
infection and MDRTB, with prevalence ratio for HIV-infected versus HIV-uninfected of 0.95 
(95% CI 0.28 – 3.15) (table 2). Among previously treated cases, 87/500 (17.4%) episodes 
were MDRTB among HIV co-infected, versus 8/72 (11.1%) among HIV uninfected 
(prevalence ratio 1.57 [95% CI 0.79 – 3.09]). There was no evidence for interaction between 
HIV status and previous treatment exposure (p=0.202).    
Among previously treated cases, HIV infection was not associated with rifampicin resistance. 
102/500 (20.4%) episodes were rifampicin resistant (monoresistant or MDRTB) among HIV 
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infected, versus 9/72 (12.5%) among HIV uninfected (prevalence ratio 1.63 [95% CI 0.86 – 
3.08]) (table 2).  
 
DISCUSSION 
Although CNR among miners have fallen since 2002, they remain very high. Reasons for the 
observed decrease are not clear, but may include higher antiretroviral therapy coverage, 
which we will investigate in future work. We do not know of any factors that may have 
caused completeness of notifications to change over the study period.  High CNR may partly 
be attributed to case detection through annual workforce surveillance by chest radiograph. 
Comparisons with South African national rates must consider the denominator population of 
a workforce with strong tuberculosis risk factors.   
Despite CNR decreasing overall, MDRTB CNR in company A increased. Although several 
factors may be contributory, including artefact due to higher DST coverage, we consider this 
to be unlikely to account for all the increase in MDRTB CNR seen here; which is more likely 
to be a true increase as rifampicin resistance is superimposed on existing isoniazid 
resistance. Isoniazid monoresistance CNR changed by year in company A, but without 
evidence of linear increase in either company. Previous studies suggest that rifampicin 
levels are reduced among HIV-infected individuals [11] and that individual pharmacokinetic 
variability accounts for some rifampicin resistance [12]. Drugs used in mine health services 
are obtained from approved national sources and rifampicin under-dosing is unlikely. We do 
not have data on treatment adherence in this population but are not aware of any factors that 
may have caused it to change with time.   
Proportions with rifampicin- and multi-drug resistance are higher than reported previously in 
similar populations [5, 6]. Such resistance was associated with previous treatment exposure, 
consistent with acquisition of resistance due to previous inadequate treatment, as seen in a 
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similar workforce [13]. However, two studies using genotyping, one in a mining population, 
suggest that circulating MDR strains are also transmitted among previously treated 
individuals [8, 14] and this will account for a proportion of the resistance seen here.  
HIV infection was not a strong risk factor for drug resistance. A South African national survey 
in 2001-2 suggested some association between HIV infection and MDRTB in previously 
treated cases [15]. Similarly for rifampicin monoresistance, these results do not exclude an 
effect of HIV infection among previously treated cases, but numbers are insufficient to 
conclude that observations are not due to chance. International data, collated in a systematic 
review, were also inconclusive on this point [16]. 
There is inherent uncertainty regarding population CNRs of drug-resistant disease in this 
observational study as numerators are relatively small. Bias cannot be excluded due to 
suboptimal DST coverage. DST may have been more likely to be performed when 
resistance was suspected, resulting in overestimation of observed proportions, where DST 
was not done systematically. It is unlikely that changes in proportions with MDRTB are 
entirely due to changes in testing coverage as our data show increased DST coverage over 
the study period, which may reflect less selective, more routine testing, or possibly an 
increase in proportions with suspected drug resistance. 
HIV status was not documented for all episodes notified, but HIV prevalence among 
episodes with known status was very high throughout the study period. Strategies for 
improved HIV testing and treatment coverage are essential to reduce risk of tuberculosis 
[17], particularly in view of recent evidence [18, 19, 20] and revised World Health 
Organization recommendations for early antiretroviral therapy for all HIV-infected individuals 
with active tuberculosis [21]. This is particularly important for those with drug-resistant 
tuberculosis and HIV, among whom mortality is high [22, 23, 24].  
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This study was conducted in a period preceding widespread IPT. There has been concern 
that IPT may lead to increased isoniazid resistance, although there is no evidence for this 
[25, 26]. Considering that the intervention began in parts of this workforce from June 2007, 
the period of this analysis is likely to be too early to reflect its impact. Furthermore, IPT is 
unlikely to have resulted in the increase in MDRTB seen here and there was no evidence of 
increasing isoniazid monoresistance. 
CONCLUSIONS 
Despite decreasing tuberculosis CNR, MDRTB CNR and proportions of episodes with drug 
resistance increased in the larger company. It is essential to ensure cure of first episodes to 
prevent acquired resistance and to ensure prompt recognition, treatment and cure of drug-
resistant tuberculosis to prevent further resistance and transmission. Tuberculosis control in 
this high risk population is challenging and improved coverage of culture, DST and HIV 
testing is essential to ensure appropriate treatment for tuberculosis. 
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TABLES AND FIGURES 
Table 1: Association of antituberculous drug susceptibility patterns with treatment history, 
2002 to 2008: Data from companies A and B combined. 
Drug susceptibility 
pattern  
Previously 
untreated episodes 
n=1547 
n (%) 
Previously treated 
episodes 
n=8842 
n (%)  
Prevalence ratio 
(95% confidence 
interval)* 
Rifampicin and isoniazid 
susceptible  
1359 (87.8) 619 (70.0) 1.0 (reference) 
Isoniazid resistant, 
rifampicin susceptible  
152 (9.8) 106 (12.0) 1.45 (1.15-1.83) 
Rifampicin resistant, 
isoniazid susceptible  
7 (0.5) 20 (2.3) 6.11 (2.60 – 14.37) 
MDR  29 (1.9) 139 (15.7) 8.78 (5.94-12.97) 
    
Isoniazid any resistance  181 (11.7) 245 (27.7) 2.41 (2.03-2.87) 
1
Prevalence ratios calculated separately for each drug susceptibility pattern compared with rifampicin 
and isoniazid susceptible episodes, ratio compares those previously treated with those previously 
untreated 
2
Total includes all retreatment episodes, plus 9 changes in DST during treatment of first tuberculosis 
episodes and 58 first treatment episodes for which DST was done on specimens taken after 30 or 
more days’ treatment exposure 
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Table 2: Multi-drug resistance, rifampicin and isoniazid resistance among tuberculosis episodes in HIV- infected and -uninfected individuals in 1 
companies A and B combined 2 
Number of episodes HIV infected:  
resistant/total1 (%) 
 
HIV uninfected: 
resistant/total1 (%) 
  
Prevalence ratio2 
(95% confidence interval) 
p-value 
(chi-squared test) 
MDR 
 
    
Previously untreated 
 
19/795 (2.4) 3/119 (2.5) 0.95 (0.28-3.15) 0.931 
Previously treated 
 
87/500 (17.4%) 8/72 (11.1) 1.57 (0.79-3.09) 0.180 
     
Any rifampicin resistance (MDR plus rifampicin monoresistance) 
 
 
Previously untreated 
 
21/795 (2.6) 5/119 (4.2) 0.63 (0.24-1.64) 0.340 
Previously treated 
 
102/500 (20.4) 9/72 (12.5) 1.63 (0.86-3.08) 0.113 
     
Any isoniazid resistance (MDR plus isoniazid monoresistance) 
 
 
Previously untreated 
 
108/795 (13.6) 12/119 (10.1) 1.35 (0.77-2.37) 0.292 
Previously treated 
 
144/500 (28.8) 18/72 (25.0) 1.15 (0.75-1.76) 0.503 
     
1
Denominators include all registered episodes with DST available and known HIV status (n=1480) plus six cases of change of drug susceptibility during 3 
treatment in individuals with known HIV status (total=1486) 4 
2
Prevalence of resistance pattern specified, in HIV infected versus uninfected5 
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Figure 1: Flow chart of numbers of tuberculosis episodes included at each stage of results 6 
and analyses 7 
 Company A Company B 
 
Total number of episodes 
registered 2002-8 (CNR) 
4268 1472 
   
Episodes culture positive for M. 
tuberculosis  
2461 Data not available 
   
Culture positive episodes with 
DST available for rifampicin and 
isoniazid 
Not reported at this stage 458 
   
Re-registrations excluded 78 43 
   
Corrected number after 
excluding re-registrations 
2383 415 
   
Excluded from DST coverage 
calculations as M. tuberculosis 
and NTM isolated in culture 
133 Not applicable 
   
Culture positive episodes with 
M. tuberculosis only isolated 
2250 Not applicable 
   
Registered culture positive M. 
tuberculosis with DST available 
2007 415 
 
Including change of DST during 
treatment of a registered 
episode 
 
2012 
 
419 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
22 
 
Figure 2: Tuberculosis case notifications and episodes of culture positive M. tuberculosis with drug susceptibility testing (DST) results available 16 
for at least rifampicin and isoniazid, per 100000 per year, 2002 to 2008, companies A (left) and B (right). Table shows numbers of cases 17 
notified for each year, per company, and number (percentage) culture positive M. tuberculosis with DST. 18 
 19 
 
Year 
 
2002 
 
2003 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
Total  
Comp A 
  
2002 
 
2003 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
Total  
Comp B 
 
Cases 
notified 
 
704 
 
717 
 
697 
 
599 
 
578 
 
482 
 
491 
 
4268 
  
221 
 
247 
 
222 
 
189 
 
190 
 
199 
 
204 
 
1472 
Number 
(%) culture 
positive 
with DST 
 
373 
(53.0) 
 
400 
(55.8) 
 
323 
(46.3) 
 
252 
(42.0) 
 
 
242 
(41.9) 
 
207 
(42.9) 
 
210 
(42.8) 
 
2007 
(47.0) 
  
45 
(20.4) 
 
53 
(21.5) 
 
65 
(29.3) 
 
52 
(27.5) 
 
48 
(25.3) 
 
80 
(40.2) 
 
72 
(35.3) 
 
415 
(28.2) 
20 
Year 
Episodes per 
100000 
mean 
population 
per year 
23 
 
Figure 3: Case notification rates for drug-resistant tuberculosis 2002-8: companies A (left) and B (right) Table shows numbers of episodes per 21 
100,000 mean population as plotted 22 
 23 
Number of 
episodes 
 
2002 
 
2003 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
  
2002 
 
2003 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
 
MDR 
 
7 
 
20 
 
11 
 
17 
 
27 
 
22 
 
20 
  
4 
 
4 
 
8 
 
6 
 
8 
 
4 
 
8 
 
Rif monores. 
 
3 
 
1 
 
3 
 
1 
 
2 
 
6 
 
9 
  
0 
 
0 
 
0 
 
1 
 
0 
 
0 
 
0 
 
INH monores. 
 
48 
 
36 
 
39 
 
29 
 
15 
 
35 
 
9 
  
5 
 
7 
 
8 
 
6 
 
7 
 
7 
 
6 
24 
Episodes 
per 100000 
mean 
population 
per year 
Year  
24 
 
Figure 4: Drug resistance as a percentage of all M. tuberculosis culture positive episodes among previously untreated cases, 2002-8: 25 
companies A (left) and B (right) 26 
 27 
 28 
Numbers with 
resistance (%) 
2002 2003 2004 2005 2006 2007 2008  2002 2003 2004 2005 2006 2007 2008 
 
MDR 
2  
(0.8) 
2 
(0.7) 
2 
(0.9) 
4  
(2.2) 
7 
(3.8) 
5 
(3.7) 
3 
(2.4) 
 0 0 2 
(6.9) 
0 2 
(12.5) 
0 0 
 
Rif monores. 
1  
(0.4) 
0 2 
(0.9) 
0 1 
(0.5) 
1 
(0.7) 
2 
(1.6) 
 0 0 0 0 0 0 0 
 
INH monores. 
23  
(9.4) 
20 
(7.4) 
27 
(11.7) 
17  
(9.6) 
12 
(6.6) 
26 
(19.1) 
4 
(3.2) 
 1 
(14.3) 
3 
(16.7) 
5  
(17.2) 
4 
(17.4) 
1 
(6.3) 
4 
(9.3) 
5 
(11.4) 
Total episodes 
(denominators) 
 
245 
 
270 
 
231 
 
178 
 
182 
 
136 
 
125  
  
7 
 
18 
 
29 
 
23 
 
16 
 
43 
 
44 
29 
Percentage 
Year  
25 
 
Figure 5: Drug resistance as a percentage of all M. tuberculosis culture positive episodes among previously treated cases, 2002-8: companies 30 
A (left) and B (right)         31 
 32 
Percentage with 
resistance 
 
2002 
 
2003 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
  
2002 
 
2003 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
 
MDR 
6 
(4.7) 
17 
(13.0) 
9 
(9.7) 
13 
(17.3) 
20 
(32.8) 
17 
(23.9) 
17 
(20.0) 
 4 
(10.4) 
4 
(11.4) 
9 
(24.3) 
5 
(16.1) 
6 
(18.8) 
5 
(13.2) 
7 
(25.0) 
 
Rif monores. 
2 
(1.6) 
1 
(0.8) 
1 
(1.1) 
1  
(1.3) 
1 
(1.6) 
5 
(7.0) 
7 
(8.2) 
 0 0 0 1 
(3.2) 
0 0 1 
(3.6) 
 
INH monores. 
25 
(19.4) 
16 
(12.2) 
12 
(12.9) 
12 
(16.0) 
3 
(4.9) 
9  
(12.7) 
5 
(5.9) 
 5 
(13.2) 
4 
(11.4) 
3 
(8.1) 
3 
(9.7) 
5 
(15.6) 
3 
(7.9) 
1 
(3.6) 
Total episodes 
(denominators) 
 
129 
 
131 
 
93 
 
75 
 
61 
 
71 
 
85 
  
38 
 
35 
 
37 
 
31 
 
32 
 
38 
 
28 
Percentage 
Year 
26 
 
 33 
